Hemagen (US) gets Chagas approval:
This article was originally published in Clinica
Executive Summary
Hemagen (US) has received FDA approval to market its Chagas' disease ELISA. Chagas' disease, a progressively debilitating, insect-borne parasitic disease, can be transmitted through blood transfusions and usually kills its victims within ten years. Testing is routine in Latin American blood banks, but not in the US. The test is already marketed in South America by German major Boehringer Mannheim (see Clinica No 583, p 3), and in Brazil under Hemagen's own label. As many as 7% of the South American population have Chagas' disease.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.